Skip to content
lsd.com
WithdrawnPhase 2

ED Treatment of Suicidal Patients With Ketamine Infusion

NCT03502551 · University of California, Davis

Closed to entry
Status
Not accepting participants
Phase 2
Phase
—
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This study aims to determine if a single intravenous (IV) dose of ketamine given in the emergency department (ED) can provide a long term reduction in suicidal ideation, lower time to ED discharge, and increase discharge to home or voluntary treatment facilities all while being safe.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Suicidal ideation at 24 hours post-infusion

    Measured over 24 hours post-infusion

  • Incidence of Discharge to Outpatient vs. Inpatient Facilities

    Measured over Through ED stay, an average of 53 hours

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Measured over 1 week from enrollment.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Age ≥ 18 years * Chief complaint of suicidal thoughts with a MADRS-SI score \> 3 * Major depressive episode with MADRS \> 19 (moderate to severe) Exclusion Criteria: * Pregnancy * Psychosis * Acute intoxication with alcohol or illicit drugs * Acute withdrawal from alcohol or illicit drugs * Adults otherwise unable to consent * Concurrent, active medical illness requiring medical hospitalization * Inability to follow-up including no permanent address or valid telephone number * Patients unable to attend outpatient follow-up (no medical insurance, refusal to follow-up, no established care provider) * Specific contraindication to the use of ketamine (concern for increased intracranial or intraocular pressure, known allergy to ketamine) * Greater than 12 hours from time of ED presentation * Prisoners

Where

1 study site

FacilityCityRegionCountry
University of California Davis Medical CenterSacramentoCaliforniaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT03502551 on ClinicalTrials.gov →

Last updated in the registry 2019-05-01. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in